Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China

Purpose. To evaluate the rate of presumed endophthalmitis (EO) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections performed in an operating room (OR) under sterile conditions in mainland China. Methods. Retrospective single-center study between September 2012 and Decem...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanyun Chen, Wenbin Wei, Demetrios G. Vavvas, Feng Zhang, Haicheng She, Haiying Zhou, Lei Li, Yao Huang, Dimitrios P. Ntentakis, Xiangyu Shi
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2020/5163484
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849398057463971840
author Yanyun Chen
Wenbin Wei
Demetrios G. Vavvas
Feng Zhang
Haicheng She
Haiying Zhou
Lei Li
Yao Huang
Dimitrios P. Ntentakis
Xiangyu Shi
author_facet Yanyun Chen
Wenbin Wei
Demetrios G. Vavvas
Feng Zhang
Haicheng She
Haiying Zhou
Lei Li
Yao Huang
Dimitrios P. Ntentakis
Xiangyu Shi
author_sort Yanyun Chen
collection DOAJ
description Purpose. To evaluate the rate of presumed endophthalmitis (EO) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections performed in an operating room (OR) under sterile conditions in mainland China. Methods. Retrospective single-center study between September 2012 and December 2017 at Beijing Tongren Eye Center, Beijing, China. Intravitreal injection database was reviewed. All anti-VEGF injections were performed using a standardized sterile technique in an OR. Injection protocols included antibiotics for 3 days pre-injection, topical 5% povidone-iodine rinsing before the procedure, and post-injection antibiotics for 3 days. Results. A total of 37,830 intravitreal injections were performed at Beijing Tongren Eye Center. Three cases were managed as presumed EO (0.0079%). Positive cultures were documented in 2 of 3 cases. EO incidence following ranibizumab and conbercept administration was 0.0088% (3 in 33,930) and 0% (0 in 3,900), respectively. No significant difference was detected between the two drugs (P=0.745). Conclusions. Very low EO rates were seen in mainland China using a standardized sterile technique in an OR. However, EO could not be completely avoided.
format Article
id doaj-art-a5e79f3693ea466a9d13596715c4a07d
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-a5e79f3693ea466a9d13596715c4a07d2025-08-20T03:38:44ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/51634845163484Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in ChinaYanyun Chen0Wenbin Wei1Demetrios G. Vavvas2Feng Zhang3Haicheng She4Haiying Zhou5Lei Li6Yao Huang7Dimitrios P. Ntentakis8Xiangyu Shi9Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaBeijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USABeijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaBeijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaBeijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaBeijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaBeijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USABeijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaPurpose. To evaluate the rate of presumed endophthalmitis (EO) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections performed in an operating room (OR) under sterile conditions in mainland China. Methods. Retrospective single-center study between September 2012 and December 2017 at Beijing Tongren Eye Center, Beijing, China. Intravitreal injection database was reviewed. All anti-VEGF injections were performed using a standardized sterile technique in an OR. Injection protocols included antibiotics for 3 days pre-injection, topical 5% povidone-iodine rinsing before the procedure, and post-injection antibiotics for 3 days. Results. A total of 37,830 intravitreal injections were performed at Beijing Tongren Eye Center. Three cases were managed as presumed EO (0.0079%). Positive cultures were documented in 2 of 3 cases. EO incidence following ranibizumab and conbercept administration was 0.0088% (3 in 33,930) and 0% (0 in 3,900), respectively. No significant difference was detected between the two drugs (P=0.745). Conclusions. Very low EO rates were seen in mainland China using a standardized sterile technique in an OR. However, EO could not be completely avoided.http://dx.doi.org/10.1155/2020/5163484
spellingShingle Yanyun Chen
Wenbin Wei
Demetrios G. Vavvas
Feng Zhang
Haicheng She
Haiying Zhou
Lei Li
Yao Huang
Dimitrios P. Ntentakis
Xiangyu Shi
Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China
Journal of Ophthalmology
title Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China
title_full Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China
title_fullStr Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China
title_full_unstemmed Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China
title_short Incidence of Endophthalmitis after Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operating Room in China
title_sort incidence of endophthalmitis after intravitreal anti vascular endothelial growth factor injections in an operating room in china
url http://dx.doi.org/10.1155/2020/5163484
work_keys_str_mv AT yanyunchen incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT wenbinwei incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT demetriosgvavvas incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT fengzhang incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT haichengshe incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT haiyingzhou incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT leili incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT yaohuang incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT dimitriospntentakis incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina
AT xiangyushi incidenceofendophthalmitisafterintravitrealantivascularendothelialgrowthfactorinjectionsinanoperatingroominchina